Enimmune Corporation (TPEX:6564)

Enimmune Income Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	48.19	39.92	43.49	188.42	109.82
Revenue Growth (YoY)	20.74%	-8.23%	-76.92%	71.56%	380.07%
Cost of Revenue	40.18	25.69	66.87	167.57	71.1
Gross Profit	8.02	14.23	-23.37	20.84	38.72
Selling, General & Admin	77.71	80.57	80.66	54.96	42.57
Research & Development	117.13	84.95	139.27	247.38	54.76
Operating Expenses	193.26	165.37	220.1	307.26	97.39
Operating Income	-185.24	-151.14	-243.48	-286.42	-58.67
Interest Expense	-4.01	-2.2	-0.98	-0.32	-0.23
Interest & Investment Income	3.58	2.58	1.94	1.29	2.39
Currency Exchange Gain (Loss)	-	-0.6	-0.34	7.45	0.01
Other Non Operating Income (Expenses)	21.14	-14.21	5.16	10.9	9.25
Pretax Income	-164.54	-165.57	-237.69	-267.09	-47.25
Earnings From Continuing Operations	-164.54	-165.57	-237.69	-267.09	-47.25
Minority Interest in Earnings	0.19	8.03	13.95	19.12	-
Net Income	-164.35	-157.55	-223.74	-247.96	-47.25
Net Income to Common	-164.35	-157.55	-223.74	-247.96	-47.25
Shares Outstanding (Basic)	72	72	66	64	60
Shares Outstanding (Diluted)	72	72	66	64	60
Shares Change (YoY)	0.78%	8.70%	3.03%	6.44%	12.50%
EPS (Basic)	-2.28	-2.20	-3.40	-3.88	-0.79
EPS (Diluted)	-2.28	-2.20	-3.40	-3.88	-0.79
Free Cash Flow	-147.43	-144.25	-138.13	-200.98	-74.53
Free Cash Flow Per Share	-2.04	-2.02	-2.10	-3.15	-1.24
Gross Margin	16.63%	35.64%	-53.74%	11.06%	35.26%
Operating Margin	-384.36%	-378.66%	-559.79%	-152.01%	-53.42%
Profit Margin	-341.01%	-394.70%	-514.42%	-131.60%	-43.02%
Free Cash Flow Margin	-305.91%	-361.39%	-317.59%	-106.67%	-67.86%
EBITDA	-176.17	-145.53	-237.71	-280.06	-50.19
EBITDA Margin	-	-	-	-148.64%	-45.70%
D&A For EBITDA	9.07	5.61	5.77	6.35	8.49
EBIT	-185.24	-151.14	-243.48	-286.42	-58.67
EBIT Margin	-	-	-	-152.01%	-53.42%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.